Vyth-Dreese F A, Van Kooyk Y, Dellemijn T A, Melief C J, Figdor C G
Division of Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Amsterdam.
Immunology. 1993 Feb;78(2):244-51.
Human recombinant interleukin-4 (rIL-4) was studied for its capacity to inhibit rIL-2-induced lymphoid cell aggregation. In contrast to rIL-2, rIL-4 was unable to induce cluster formation by itself. However, when added simultaneously with rIL-2 to cultures of freshly isolated peripheral blood lymphocytes (PBL), rIL-4 inhibited cell aggregation in a dose-dependent way. In contrast, PBL, preactivated by a 4-day culture in the presence of 500 U/ml rIL-2, were not inhibited in their adhesive capacity by rIL-4. Inhibition of cell aggregation was most prominent at 24 hr and virtually lost after 72 hr of culture. Phenotypical analysis revealed that rIL-4, with similar kinetics, decreased the rIL-2-mediated up-regulation of the CD2, CD54 and CD49e adhesion molecules. In addition, it was observed that up-regulation of the activation epitope on CD11a recognized by the mAb NKI-L16, was prevented. During 24hr of culture rIL-4 itself did not alter the expression of these antigens. Blocking experiments with mAb directed against adhesion structures did not reveal a direct role for CD49e, but obviously demonstrated involvement of CD11a/CD18-CD54 and CD2-CD58 interactions in the rIL-2-induced adhesion. Therefore, rIL-4 appears to inhibit the early phase of rIL-2-induced aggregation by preventing the up-regulation of CD54 and CD2 antigens and by inhibiting the generation of the activated state of the CD11a/CD18 receptor.
对重组人白细胞介素-4(rIL-4)抑制rIL-2诱导的淋巴细胞聚集的能力进行了研究。与rIL-2不同,rIL-4自身无法诱导细胞簇形成。然而,当与rIL-2同时添加到新鲜分离的外周血淋巴细胞(PBL)培养物中时,rIL-4以剂量依赖的方式抑制细胞聚集。相比之下,在500 U/ml rIL-2存在下经4天培养预激活的PBL,其黏附能力不受rIL-4抑制。细胞聚集的抑制在24小时时最为显著,培养72小时后几乎消失。表型分析显示,rIL-4以相似的动力学降低了rIL-2介导的CD2、CD54和CD49e黏附分子的上调。此外,观察到单克隆抗体NKI-L16识别的CD11a上激活表位的上调受到抑制。在24小时培养期间,rIL-4自身并未改变这些抗原的表达。针对黏附结构的单克隆抗体阻断实验未揭示CD49e的直接作用,但明显证明了CD11a/CD18-CD54和CD2-CD58相互作用参与rIL-2诱导的黏附。因此,rIL-4似乎通过阻止CD54和CD2抗原的上调以及抑制CD11a/CD18受体激活状态的产生来抑制rIL-2诱导聚集的早期阶段。